Clinical pharmacology and pharmacodynamics of irinotecan: A review

Annals of the New York Academy of Sciences

Volumn 803, Issue , 1996, Pages 164-172

  Chabot, Guy G ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ALKALOID; IRINOTECAN;

ANTINEOPLASTIC ACTIVITY; CLINICAL PHARMACOLOGY; CONFERENCE PAPER; DIARRHEA; HUMAN; LEUKOPENIA; NAUSEA; NEUTROPENIA; PHARMACODYNAMICS; VOMITING;

EID: 0030469167     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb26385.x     Document Type: Conference Paper

References (53)

1. WALL, M. E., M. C. WANI, C. E. COOK, K. H. PALMER, A. T. MCPHAIL & G. A. SIM. 1966. Plant antitumor agents I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 88: 3888-3890.
2. LI, L. H., T. J. FRASER, E. J. OLIN & B. K. BHUYAN. 1972. Action of camptothecin on mammalian cells in cultures. Cancer Res. 32: 2643-2650.
3. DREWINKO, B., E. J. FREIREICH & J. A. GOTTLIEB. 1974. Lethal activity of camptothecin sodium on human lymphoma cells. Cancer Res. 3-4: 747-750.
4. GALLO, R. C., J. WHANG-PENG & R. H. ADAMSON. 1971. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J. Natl. Cancer Inst. 46: 789-795.
5. GOTTLIEB, J. A., A. M. GUARINO, J. B. CALL, V. T. OLIVERIO & J. B. BLOCK. 1970. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother. Rep. 54: 461-470.
6. GOTTLIEB, J. A. & J. K. LUCE. 1972. Treatment of malignant melanoma with camptothecin (NSC 100880). Cancer Chemother. Rep. 56: 103-105.
7. MOERTEL, C. G., A. J. SCHUTT, R. J. REITMEIER & R. G. HAHN. 1972. Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastro-intestinal cancer. Cancer Chemother. Rep. 56: 95-101.
8. MUGGIA, F. M., P. J. CREAVEN, H. H. HANSEN & O. S. SELAWRY. 1972. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880): correlation with preclinical studies. Cancer Chemother. Rep. 56: 515-521.
9. CREAVEN, P. J., L. M. ALLEN & F. M. MUGGIA. 1972. Plasma camptothecin (NSC 100880) levels during a 5-day course of treatment: Relation to dose and toxicity. Cancer Chemother. Rep. 56: 573-578.
10. SCHAEPPI, V., R. W. FLEISCHMAN & D. A. COONEY. 1974. Toxicity of camptothecin (NSC 100880). Cancer Chemother. Rep. 58: 25-36.
11. KUNIMOTO, T., K. NITTA, T. TANAKA, N. UEHARA, H. BABA, M. TAKEUCHI, T. YOKOKURA, S. SAWADA, T. MIYASAKA & M. MUTAI. 1987. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 47: 5944-5947.
12. TSURUO, T., T. MATSUZAKI, M. MATSUSHITA, H. SAITO & T. YOKOKURA. 1988. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol. 21: 71-74.
13. BISSERY, M. C., A. MATHIEU-BOUE & F. LAVELLE. 1991. Preclinical evaluation of CPT-11, a camptothecin derivative. Proc. Am. Assoc. Cancer Res. 32:402 (abstract).
14. HOUGHTON, P. J., P. J. CHESHIRE, J. C. HALLMAN, M. C. BISSERY, A. MATHIEU-BOUE & J. A. HOUGHTON. 1993. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res. 53: 2823-2829.
15. VASSAL, G., J. MORIZET, M. C. BISSERY, I. BOLAND, P. ARDOUIN, A. MATHIEU-BOUE, & A. GOUYETTE. 1994. Activity of the camptothecin analog CPT-11 (irinotecan) against medulloblastoma xenographts. Proc. Am. Assoc. Cancer Res. 35: 366 (abstract).
16. BISSERY, M. C., P. VRIGNAUD, F. LAVELLE & G. G. CHABOT. 1996. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anti-Cancer Drugs. Anti-Cancer Drugs 7: 437-460.
17. HSIANG, Y. H., R. HERTZBERG, S. HECHT & L. F. LIU. 1985. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260: 14873-14878.
18. HSIANG, Y. H. & L. F. LIU. 1988. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48: 1722-1726.
19. HSIANG, Y. H., L. F. LIU, M. E. WALL, M. C. WANI, A. W. NICHOLAS, G. MANIKUMAR, S. KIRSCHENBAUM, R. SILBER & M. POTMESIL. 1989. DNA topoisomerase I mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res. 49: 4835-4839.
20. KESSEL, D., H. B. BOSMANN & K. LOHR. 1972. Camptothecin effects on DNA synthesis in murine leukemia cells. Biochem. Biophys. Acta 269: 210-216.
21. WANG, J. C. 1985. DNA topoisomerases. Annu. Rev. Biochem. 54: 665-697.
22. LIU, L. F. 1989. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58: 351-375.
23. GUPTA, R. S., R. GUPTA, B. ENG, R. B. LOCK, W. E. Ross, R. P. HERTZBERG, M. J. CARANFA & R. K. JOHNSON. 1988. Camptothecin-resistant mutants of chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res. 48: 6404-6410.
24. KANZAWA, F., Y. SUGIMOTO, K. MINATO, K. KASAHARA, M. BUNGO, K. NAKAGAWA, Y. FUJIWARA, F. LIU & N. SAIJO. 1990. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human small cell lung cancer: Characterization and mechanism of resistance. Cancer Res. 50: 5919-5924.
25. SUGIMOTO, Y., S. TSUKAHARA, T. OH-HARA, T. ISOE & T. TSURUO. 1990. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 50: 6925-6930.
26. TAMURA, H., C. KOHCHI & R. YAMADA. 1991. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res. 51: 1129-1136.
27. CHEN, A. Y., C. YU, M. POTMESIL, M. E. WALL, M. C. WANI & L. F. LIU. 1991. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res. 51: 6039-6044.
28. KAWATO, Y., M. AONUMA, Y. HIROTA, H. KUGA & K. SATO. 1991. Intracellular roles of SN-38, a metabolite of the camptothecin derivative, CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51: 4187-4191.
29. OHNO, R., K. OKADA, T. MASAOKA, A. KURAMOTO, T. ARIMA, Y. YOSHIDA, H. ARIYOSHI, M. ICHIMARU, Y. SAKAI, M. OGURO, Y. ITO, Y. MORISHIMA, S. YOKOMAKU & K. OTA. 1990. An early phase II study of CPT-11: A new derivative of camptothecin for the treatment of leukemia and lymphoma. J. Clin. Oncol. 8: 1907-1912.
30. TAGUCHI, T., A. WAKUI & K. HASEGAWA. 1990. Phase I clinical study of CPT-11. Research Group of CPT-11. Jpn. J. Cancer Chemother., 17: 115-120.
31. NEGORO, S., M. FUKUOKA, N. MASUDA, M. TAKADA, Y. KUSUNOKI, K. MATSUI, N. TAKIFUJI, S. KUDOH, H. NIITANI & T. TAGUCHI. 1991. Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advance non-small cell lung cancer. J. Natl. Cancer Inst. 83: 1164-1168.
32. OHE, Y., Y. SASAKI, T. SHINKAI, K. EGUCHI, T. TAMURA, A. KOJIMA, H. KUNIKANE, H. OKAMOTO, A. KARATO, H. OHMATSU, F. KANZAWA & N. SAIJO. 1992. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J. Natl. Cancer Inst. 84: 972-974.
33. ROTHENBERG, M. L., J. G. KUHN, H. A. BURRIS III, J. NELSON, J. R. ECKARDT, M. TRISTAN-MORALES, S. G. HILSENBECK, G. R. WEISS, L. S. SMITH, G. I. RODRIGUEZ, M. K. ROCK & D. D. VON HOFF. 1993. Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol. 11: 2194-2204.
34. ROWINSKY, E. K., L. B. GROCHOW, D. S. ETTINGER, S. E. SARTORIUS, B. G. LUBEJKO, T. L. CHEN, M. K. ROCK & R. C. DONEHOWER. 1994. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino-]carbonyl-oxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res. 54: 427-436.
35. FUKUOKA, M., H. NITANI, A. SUZUKI, M. MOTOMIYA, K. HASEGAWA, Y. NISHIWAKI, T. KURIYAMA, Y. ARIYOSHI, S. NEGORO, N. MASUDA, S. NAKAJIMA & T. TAGUCHI. 1992. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J. Clin. Oncol. 10: 16-20.
36. BURRIS, H. A., M. L. ROTHENBERG, J. G. KUHN & D. D. VON HOFF. 1992. Clinical trials with the topoisomerase I inhibitors. Semin. Oncol. 19: 663-669.
37. SLICHENMYER, W. J., E. K. ROWINSKY, R. C. DONEHOWER & S. H. KAUFMANN. 1993. The current status of camptothecin analogues as antitumor agents (review). J. Natl. Cancer Inst. 85: 271-291.
38. MASUDA, N., M. FUKUOKA, Y. KUSUNOKI, K. MATSUI, N. TAKIFUJI, S., KUDOH, S. NEGORO, M. NISHIOKA, K. NAKAGAWA & M. TAKADA. 1992. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol., 10: 1225-1229.
39. OGAWA, M. & T. TAGUCHI. 1992. Clinical studies with CPT-11: The Japanese experience. 1992. Ann. Oncol. 3 (Suppl. 1): 118 (abstract 239).
40. CATIMEL, G., G. G. CHABOT, J. P. GUASTALLA, A. DUMORTIER, C. COTE, C. ENGEL, A. GOUYETTE, A. MATHIEU-BOUE, M. MAHJOUBI & M. CLAVEL. 1995. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann. Oncol. 6: 133-140.
41. DEFORNI, M., R. BUGAT, G. G. CHABOT, S. CULINE, J. M. EXTRA, A. GOUYETTE, I. MADELAINE, M. E. MARTY & A. MATHIEU-BOUE. 1994. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan administered on a weekly schedule in cancer patients. Cancer Res. 54: 4347-4354.
42. ABIGERGES, D., G. G. CHABOT, J. P. ARMAND, P. HERAIT, A. GOUYETTE & D. GANDIA. 1995. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J. Clin. Oncol. 13: 210-221.
43. BARILERO, I., D. GANDIA, J. P. ARMAND, A. MATHIEU-BOUE, M. RE, A. GOUYETTE & G. G. CHABOT. 1992. Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography - Application to plasma pharmacokinetic studies in cancer patients. J. Chromatogr. (Biomed. Appl.) 575: 275-280.
44. CHABOT, G. G., D. ABIGERGES, G. CATIMEL, S. CULINE, M. DEFORNI, J. M. EXTRA, M. MAHJOUBI, P. HERAIT, J. P. ARMAND, R. BUGAT, M. CLAVEL & M. E. MARTY. 1995. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann. Oncol 6: 141-151.
45. ROWINSKY, E. K., L. B. GROCHOW, C. B. HENDRICKS, D. S. ETTINGER, A. A. FORASTIERE, L. A. HUROWITZ, W. P. MCGUIRE, S. E. SARTORIUS, B. G. LUBEJKO, S. H. KAUFMANN & R. C. DONEHOWER. 1992. Phase I and pharmacology study of topotecan: A novel topoisomerase I inhibitor. J. Clin. Oncol. 10: 647-656.
46. KANEDA, N., H. NAGATA, T. FURUTA & T. YOKOKURA. 1990. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 50: 1715-1720.
47. KANEDA, N. & T. YOKOKURA. 1990. Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res. 50: 1721-1725.
48. MASUDA, N., M. FUKUOKA, S. KUDOII, K. MATSUI, Y. KUSUNOKI, M. TAKADA, K. NAGAKAWA, T. HIRASHIMA, H. TSUKADA, T. YANA, A. YOSHIKAWA, A. KUBO, E. MATSUURA, T., MITTA, N. TAKIFUJI, K. TERAKAWA & S. NEGORO. 1994. Phase I and pharmacologie study of irinotecan and etoposide with recombinant human granulo-cyte colony-stimulating factor support for advanced lung cancer. J. Clin. Oncol. 12: 1833-1841.
49. TSUJI, T., N. KANEDA, K. KADO, T. YOKOKURA, T. YOSIIIMOTO & D. STURU. 1991. CPT-Il converting enzyme from rat serum: Purification and some properties. J. Pharmacobiodyn. 14: 341-349.
50. CHABOT, G. G. 1994. Factors involved in clinical pharmacology variability in oncology (review). Anticancer Res. 14: 2269-2272.
51. GUPTA, E., T. M. LESTINGI, R. MICK, J. RAMIREZ, E. E. VOKES & M. J. RATAIN. 1994. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res. 54: 3723-3725.
52. GANDIA, D., D. ABIGERGES, J. P. ARMAND, G. G. CHABOT, L. DA COSTA & M. DE FORNI. 1993. CPT-11-Induced cholinergic effects in cancer patients. J. Clin. Oncol. 11: 196-197 (letter).
53. CHABOT, G. G. 1995. Limited sampling models for simultaneous estimation of the phar-macokinetics of irinotecan and its active metabolite SN-38. Cancer Chemother. Phar-macol. 36: 463-472.